Boston Scientific Corporation (BSX)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,348,703 |
| Open | 104.85 |
| Previous Close | 103.79 |
| Day's Range | 103.86 - 105.57 |
| 52-Week Range | 65.52 - 107.17 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BSX
There is no company description available. [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial StatementsNews
Boston Scientific announces completion of €1.5 billion offering of senior notes
MARLBOROUGH, Mass. , Feb. 26, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.
Balloon Catheters Patent Landscape Report 2025, with Profiles of Cook Medical Technologies, Boston Scientific Scimed, Scimed Life Systems, Terumo Corp and Advanced Cardiovascular System
Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Balloon Catheters Patent Landscape Report" has been added to ResearchAndMarkets.com's offering.
Boston Scientific announces pricing of €1.5 billion of senior notes
MARLBOROUGH, Mass. , Feb. 21, 2025 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
MARLBOROUGH, Mass. , Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.
What's Behind The 130% Rise In BSX Stock?
Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest sto...
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Company Participants Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan ...
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific announces results for fourth quarter and full year 2024
MARLBOROUGH, Mass. , Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported ...
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Abl...
Boston Scientific Jumps Ahead of Earnings
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.
Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
On Wednesday, Boston Scientific Corporation BSX agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral arte...
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease MARLBOROUGH...
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
MARLBOROUGH, Mass. , Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P.
Boston Scientific Corporation: Solid Financials And Upward Continuation
Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. The smooth upward movement of the stock indicates the quality of its investor base. Stro...
FDA classifies recall of Boston Scientific catheters as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of minimally invasive surgery as "most serious".
Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace
NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth Stein, MD, and Sco...
Jim Cramer talks companies that joined the $100 billion club this year
'Mad Money' host Jim Cramer looks at companies that joined the $100 billion club this year.
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.
Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass. , Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (...
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , ...
Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-An...